Logo CICANCER

Old CIC Events

Servicio de Patología Molecular Comparada del CIC 21/04/2023

Servicio de Patología Molecular Comparada del CIC

Equipo de PMC — Centro de Investigación del Cáncer, Salamanca

How does DNA replication initiate in animal cells? 20/04/2023

How does DNA replication initiate in animal cells?

Karim Labib — University of Dundee, Dundee, UK

EMT and plasticity trajectories in development and disease 13/04/2023

EMT and plasticity trajectories in development and disease

Ángela Nieto — Instituto de Neurociencias (CSIC-UMH), Alicante, Spain

N6-ADENOSINE METHYLTRANSFERASE COMPLEX REGULATOR ZC3H13 DELETION AS MALIGNANT PROGNOSIS FACTOR IN PROSTATE CANCER 30/03/2023

N6-ADENOSINE METHYLTRANSFERASE COMPLEX REGULATOR ZC3H13 DELETION AS MALIGNANT PROGNOSIS FACTOR IN PROSTATE CANCER

Óscar Monteagudo — Epitranscriptomic and Cancer Lab, Centro de Investigación del Cáncer (CIC)

Functions of METTL3 in stem cells and cancer 23/03/2023

Functions of METTL3 in stem cells and cancer

Francesca Aguilo — Umea University, Sweden

Specific killing of BRCA1-deficient cancer cells by depletion of EXO1 16/03/2023

Specific killing of BRCA1-deficient cancer cells by depletion of EXO1

Haico van Attikum — Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands

RAS-p110a signalling controls macrophage-derived inflammatory response by favouring transendothelial migration and phagocytic capacity. 09/03/2023

RAS-p110a signalling controls macrophage-derived inflammatory response by favouring transendothelial migration and phagocytic capacity.

Alejandro Rosell Jiménez — Centro de Investigación del Cáncer (CSIC-USAL), Salamanca

Connecting myeloid cell metabolism and function 02/03/2023

Connecting myeloid cell metabolism and function

David Sancho Madrid — Centro Nacional de Investigaciones Cardiovasculares de Madrid

AHR adjusts senescence and stemness: impact in tissue regeneration and tumor progression 23/02/2023

AHR adjusts senescence and stemness: impact in tissue regeneration and tumor progression

Pedro M. Fernández Salguero — Universidad de Extremadura, Badajoz.

ctDNA in cancer care 16/02/2023

ctDNA in cancer care

Elza de Bruin — Director Translational Medicine, AstraZeneca, Cambridge, UK